Metrics as of 10/13/2026, 08:48 AM (Berlin time), refresh in progress.
PolyPid Stock
PolyPid Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- CEO
- Dikla Czaczkes Akselbrad
- Employees
- 72
- Market cap
- $93 M
- IPO
- 26/06/2020
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The…
PolyPid stock: price history
1D
-3.4%
1W
-5.5%
1M
-5.8%
6M
+9.7%
YTD
+11.8%
1Y
+45.2%
2Y
+39.8%
5Y
-97.9%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~10% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about PolyPid
Analyst assessment of PolyPid
PRICE TARGET LOW
US$12.00
CONSENSUS
US$12.50
MEDIAN
US$12.50
PRICE TARGET HIGH
US$13.00
0
STRONG BUY
8
BUY
1
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 21/07/2026
PolyPid stock metrics
P/E
-3.28
P/B
20.38
EV/EBITDA
-2.95
RETURN ON EQUITY
-145.7%
NET MARGIN
0.0%
DEBT/EQUITY
0.29
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
57.6%
FLOAT SHARES
10,993,841
AVG. DAILY VOLUME (30D)
94,161
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about PolyPid stock
What does PolyPid do?
PolyPid Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in Israel.
The CEO is Dikla Czaczkes Akselbrad, the company employs around 72 people.
The IPO was on 26/06/2020; the stock trades on NASDAQ under the ticker PYPD.
What do analysts say about PolyPid stock?
9 analysts rate the stock, the consensus is Buy (as of 21/07/2026).
The average price target is US$12.50, ranging from US$12.00 to US$13.00, with a median of US$12.50.
This is an external assessment, not a statement by Market Jury.
When does PolyPid report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -10% stronger than usual.
Does PolyPid pay a dividend?
No, PolyPid currently does not pay a dividend.
Which stocks are comparable to PolyPid?
Comparable stocks include Alpha Tau Medical, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get PolyPid stock analyzed?
Clicking "Analyze stock" lets five strategies assess PolyPid against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.